H.C. Wainwright Thinks Diffusion Pharmaceuticals Inc’s Stock is Going to Recover


In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Diffusion Pharmaceuticals Inc (DFFN), with a price target of $1.25. The company’s shares closed yesterday at $0.32, close to its 52-week low of $0.31.

Ramakanth noted:

“We maintain our Buy rating of DFFN and our 12-month price target of $1.25 per share. We derive our price target based on a risk-adjusted NPV analysis of projected TSC revenues through 2030 assuming a 12% discount rate and 2% terminal growth rate.”

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.8% and a 33.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as IntelGenx Technologies, Leap Therapeutics Inc, and Tyme Technologies Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Diffusion Pharmaceuticals Inc with a $1.25 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.08 and a one-year low of $0.31. Currently, Diffusion Pharmaceuticals Inc has an average volume of 246.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Diffusion Pharmaceuticals, Inc. is a clinical stage company which engages in the provision of oncology-focused biotechnology. It involves in research and development, and manufacture of drug products for the treatment of cancer in combination with radiation and chemotherapy.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts